[go: up one dir, main page]

MX2007013468A - Composiciones que contienen tanaproget micronizado. - Google Patents

Composiciones que contienen tanaproget micronizado.

Info

Publication number
MX2007013468A
MX2007013468A MX2007013468A MX2007013468A MX2007013468A MX 2007013468 A MX2007013468 A MX 2007013468A MX 2007013468 A MX2007013468 A MX 2007013468A MX 2007013468 A MX2007013468 A MX 2007013468A MX 2007013468 A MX2007013468 A MX 2007013468A
Authority
MX
Mexico
Prior art keywords
compositions containing
containing micronized
micronized tanaproget
tanaproget
butylafced
Prior art date
Application number
MX2007013468A
Other languages
English (en)
Inventor
Ramarao Chatlapalli
Arwinder Nagi
Shamim Hasan
Rolland Carson
Mohamed Ghorab
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007013468A publication Critical patent/MX2007013468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proveen composiciones farmaceuticas que contienen tanaproget micronizado, o una sal farmaceuticamente aceptable del mismo, celulosa microcristalina, croscarmelosa de sodio, lauril sulfato de sodio, hidroxianisol butilado, povidona y estearato de magnesio; ademas se describen procedimientos de fabricacion.
MX2007013468A 2005-04-28 2006-04-26 Composiciones que contienen tanaproget micronizado. MX2007013468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67559905P 2005-04-28 2005-04-28
PCT/US2006/016025 WO2007030153A2 (en) 2005-04-28 2006-04-26 Compositions containing micronized tanaproget

Publications (1)

Publication Number Publication Date
MX2007013468A true MX2007013468A (es) 2008-01-21

Family

ID=37836301

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013468A MX2007013468A (es) 2005-04-28 2006-04-26 Composiciones que contienen tanaproget micronizado.

Country Status (14)

Country Link
US (2) US8343965B2 (es)
EP (1) EP1874278B1 (es)
JP (3) JP5149161B2 (es)
CN (1) CN101166521A (es)
AT (1) ATE434434T1 (es)
AU (1) AU2006287925B2 (es)
BR (1) BRPI0610438A2 (es)
CA (1) CA2603817C (es)
DE (1) DE602006007453D1 (es)
DK (1) DK1874278T3 (es)
ES (1) ES2327783T3 (es)
MX (1) MX2007013468A (es)
PL (1) PL1874278T3 (es)
WO (1) WO2007030153A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
ES2327783T3 (es) 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
DE602006013114D1 (de) * 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
BRPI0610433A2 (pt) * 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
BRPI0611250A2 (pt) 2005-06-09 2011-02-15 Wyeth Corp composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
WO2011074961A1 (en) 2009-12-18 2011-06-23 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
JP2024530727A (ja) 2021-08-25 2024-08-23 ビーエーエスエフ ソシエタス・ヨーロピア 直接打錠補助組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
EP1175411B1 (en) * 1999-05-04 2008-02-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CN1665510A (zh) * 2002-06-25 2005-09-07 惠氏公司 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途
WO2004000801A2 (en) * 2002-06-25 2003-12-31 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
US20040127476A1 (en) * 2002-11-14 2004-07-01 Alvin Kershman Oral testosterone delivery system with improved sustained release
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
ES2306140T3 (es) * 2004-04-27 2008-11-01 Wyeth Biarilos ciclicos de carbamato y tiocarbamato que contienen cianopirrol y procedimientos para su preparacion.
BRPI0510260A (pt) * 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
AU2005269938A1 (en) * 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CN101001863B (zh) * 2004-08-13 2012-10-10 惠氏公司 坦普盖特衍生物、代谢物及其用途
WO2006031378A2 (en) * 2004-08-20 2006-03-23 Wyeth Progesterone receptor structure
DE602006013114D1 (de) 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
BRPI0610433A2 (pt) 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
JP2008539254A (ja) * 2005-04-28 2008-11-13 ワイス タナプロゲットの精製形態
ES2327783T3 (es) 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
ATE460937T1 (de) 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
BRPI0611250A2 (pt) 2005-06-09 2011-02-15 Wyeth Corp composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
US8791109B2 (en) 2014-07-29
CN101166521A (zh) 2008-04-23
US8343965B2 (en) 2013-01-01
JP2012254999A (ja) 2012-12-27
EP1874278A2 (en) 2008-01-09
BRPI0610438A2 (pt) 2012-10-23
ES2327783T3 (es) 2009-11-03
US20130142838A1 (en) 2013-06-06
JP5149161B2 (ja) 2013-02-20
WO2007030153A2 (en) 2007-03-15
WO2007030153A3 (en) 2007-08-09
JP2014205683A (ja) 2014-10-30
AU2006287925A1 (en) 2007-03-15
JP2008539264A (ja) 2008-11-13
CA2603817C (en) 2013-03-19
US20060247234A1 (en) 2006-11-02
DK1874278T3 (da) 2009-09-28
EP1874278B1 (en) 2009-06-24
AU2006287925B2 (en) 2012-03-01
ATE434434T1 (de) 2009-07-15
PL1874278T3 (pl) 2009-12-31
DE602006007453D1 (de) 2009-08-06
CA2603817A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
GEP20115303B (en) Capsule of pirfenidone
SG152240A1 (en) Pharmaceutical compositions comprising an amphiphilic starch
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
MX2008002765A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
MX2009001294A (es) Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
MX2020002841A (es) Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
NO20076288L (no) Farmasoytiske sammensetninger innbefattende imatinib og et frigivningssinkende middel
MX2009009703A (es) Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.
TW200700406A (en) Novel thiophene derivatives
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TW200716591A (en) Novel thiophene derivatives
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
HRP20090194T1 (hr) Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
TW200738670A (en) Novel thiophene derivatives
GEP20094784B (en) Sustained release pharmaceutical formulations
RU2008135718A (ru) Композиции клопидогреля бисульфата
MX2007013468A (es) Composiciones que contienen tanaproget micronizado.
CL2008001678A1 (es) Forma de dosificación farmacéutica de liberacion prolongada en forma de comprimido, que consiste de nevirapina anhidra, hipromelosa, lactosa monohidrato y estearato de magnesio; y su procedimiento de preparación, util para el tratamiento de una infeccion por vih-1.
GB2456096A (en) Crystalline form of benzothiophene compound and process for preparation thereof

Legal Events

Date Code Title Description
FG Grant or registration